| 摘要 |
Methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism are disclosed. Conditions include Alzheimer's disease, Parkinson's Disease, Friedreich's Ataxia, GLUTI-deficient Epilepsy, Leprechaunism, and Rabson- Mendenhall Syndrome, Coronary Arterial Bypass Graft, dementia, anesthesia-induced memory loss, and Huntington's Disease. |
